SCHEMBL4177624

SCHEMBL4177624

CCCCCCCCC=CCCCCCCCCOC(N)=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.61
SOAT1 P35610 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP2C19 P33261 2/20 0.61
MEN1 O00255 1/20 0.61
TP53 P04637 1/20 0.61
CYP3A4 P08684 1/20 0.61
KMT2A Q03164 1/20 0.61
KDM4E B2RXH2 2/20 0.56
CNR1 P21554 1/20 0.53
EPHX2 P34913 2/20 0.52
GMNN O75496 1/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
ALOX15 P16050 1/20 0.52
APEX1 P27695 1/20 0.52
RECQL P46063 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1416577 1.00 FAAH (0.61) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL1416574 1.00 FAAH (0.61) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL1416618 1.00 FAAH (0.61) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL1416542 1.00 FAAH (0.61) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL1416621 1.00 FAAH (0.61) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL1416544 1.00 FAAH (0.61) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL4177621 1.00 FAAH (0.61) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL11397133 0.96 FAAH (0.56) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL11393684 0.96 FAAH (0.56) FAAHSOAT1CYP1A2CYP2C19MEN1
SCHEMBL1416741 0.95 KDM4E (0.65) FAAHSOAT1CYP1A2CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204344-A1 PROCESS FOR PREPARING CUBIC PI-PHASE MONOCHALCOGENIDES B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) 2022-06-30 US claimed
EP-3939096-A1 PROCESS FOR PREPARING CUBIC PI-PHASE MONOCHALCOGENIDES B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) 2022-01-19 EP claimed
WO-2020212981-A1 PROCESS FOR PREPARING CUBIC PI-PHASE MONOCHALCOGENIDES B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) 2020-10-22 WO claimed
CN-117417265-A Lipid composition 富士胶片株式会社 2024-01-19 CN disclosed
CN-112262122-B Compound or salt and lipid particle thereof 富士胶片株式会社 2023-10-13 CN disclosed
CN-116172975-A Lipid particle, nucleic acid drug comprising same, and composition for nucleic acid delivery 富士胶片株式会社 2023-05-30 CN disclosed
CN-114728016-A Lipid composition 富士胶片株式会社 2022-07-08 CN disclosed
US-20220204344-A1 PROCESS FOR PREPARING CUBIC PI-PHASE MONOCHALCOGENIDES B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) 2022-06-30 US disclosed
CN-113924128-A Lipid composition 富士胶片株式会社 2022-01-11 CN disclosed
CN-112262122-A Compound or salt thereof, and lipid particle 富士胶片株式会社 2021-01-22 CN disclosed
WO-2013016058-A1 NOVEL BIS-NITROGEN CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY MERCK SHARP & DOHME CORP. (US) 2013-01-31 WO disclosed
US-6762175-B2 LIPOPHILIC BIOLOGICALLY ACTIVE COMPOUND CONTAINING IN ITS MOLECULAR STRUCTURE ONE OR MORE FUNCTIONAL GROUPS SELECTED FROM ALCOHOL, ETHER, PHENYL, AMINO, AMIDO, THIOL, ACID AND ESTER IN WHICH ONE GROUP IS REPLACED BY LIPOPHILIC GROUP NORSK HYDRO ASA (NO) 2004-07-13 US disclosed
EP-0977725-B1 NEW FATTY ACID DERIVATIVES CONPHARMA AS (NO) 2004-06-16 EP disclosed
US-20040063677-A1 Methods of treating disorders using lipophilic derivatives NORSK HYDRO ASA 2004-04-01 US disclosed
US-20030153544-A1 Lipophilic biologically active compound containing in its molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, acid and ester in which one group is replaced by lipophilic group CONPHARMA AS (NO) 2003-08-14 US disclosed
US-20010006962-A1 FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 2001-07-05 US disclosed
CN-1067926-C Solidifying method for forming and completely compacting powder material HUANG XIAODI (CN) 2001-07-04 CN disclosed
EP-0977725-A1 NEW FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 2000-02-09 EP disclosed
WO-1998032718-A1 NEW FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 1998-07-30 WO disclosed
CN-1154884-A Solidifying method for forming and completely compacting powder material HUANG XIAODI (CN) 1997-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010006962-A1 FATTY ACID DERIVATIVES HADH, NR1H2, NR1H3 FAAH 33/4885SOAT1 58/4885CYP1A2 207/4885
US-20040063677-A1 Methods of treating disorders using lipophilic derivatives NCEH1, NR1H2, NR1H3 FAAH 82/4885SOAT1 71/4885CYP1A2 425/4885
US-20220204344-A1 PROCESS FOR PREPARING CUBIC PI-PHASE MONOCHALCOGENIDES KDR, HRH3, HRH4 FAAH 3623/4885SOAT1 1440/4885CYP1A2 1762/4885
US-20030153544-A1 Lipophilic biologically active compound containing in its molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, acid and ester in which one group is replaced by lipophilic group TSPO, NR1H2, NR1H3 FAAH 26/4885SOAT1 56/4885CYP1A2 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.